Australia's Opyl jumps on first revenue from AI clinical trial platform

Pathkey.AI

06/06/2024 06:06

** Shares of Opyl  OPL.AX  rise as much as 9.5% to A$0.023
    ** Stock hits highest since April 29
    ** Medical research technology co secures first revenue and
customer for 'TrialGen', its platform that generates clinical
trial protocols using GenAI
    ** Trading vol double the 30-day daily moving avg
    ** Stock cuts YTD losses to ~18%

 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))